Market Intelligence, Clinical Progress, and High-Purity Reagents for Autoimmune and Transplant Refractory Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for HLA-DQA1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | HLA-DQA1/DQB1 Heterodimer Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed for native glycosylation. |
View HLA-DQA1 Products |
| Gene Delivery | HLA-DQA1 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation to preserve native conformation. |
View HLA-DQA1 Products |
| Benchmark Ab | Anti-HLA-DQ Recombinant Antibody Recombinant positive control derived from clinical-grade benchmark sequences. |
View HLA-DQA1 Products |
| Validator | HLA-DQA1 siRNA Set For target knockdown verification in cell-based assays. |
View HLA-DQA1 Products |
| Related Target A | HLA-DQB1 Obligate heterodimer partner; required for functional HLA-DQ receptor assembly. |
View HLA-DQB1 Products |
| Related Target B | HLA-DRB1 Major histocompatibility complex class II beta chain; critical for subfamily off-target counter-screening. |
View HLA-DRB1 Products |
| Related Target C | CD4 Co-receptor interacting with MHC class II; essential for functional T-cell activation assays. |
View CD4 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Heterodimer Stability & Conformation | Co-expressed HLA-DQA1/DQB1 stable heterodimers with sequence-verified linkages. |
| Allele-Specific Cross-Reactivity (e.g., DQ2.5 vs DQ8) | Allele-specific recombinant protein panels strictly verified by mass spectrometry and sequence analysis. |
| Lack of Controls | Clinical-grade benchmark antibodies included in the portfolio as positive controls. |
| False Positives in Screening | Sequence-verified siRNA knockdown sets included for specificity validation. |
Live HLA-DQA1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of HLA-DQA1 is gaining rapid momentum, primarily driven by the unmet clinical need in autoimmune diseases such as Celiac Disease and Type 1 Diabetes, as well as antibody-mediated rejection (AMR) in transplantation. Since HLA-DQA1 must pair with HLA-DQB1 to form functional cell-surface heterodimers, drug developers are shifting focus from pan-MHC class II inhibitors to allele-specific monoclonal antibodies, tolerogenic nanoparticles, and TCR-like therapeutics. As next-generation biologics enter clinical evaluation, precise molecular tools that can differentiate between closely related HLA alleles are becoming the decisive factor in R&0 success.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibodies (mAbs) | Takeda, Freeline Therapeutics | Celiac Disease, Transplant Rejection | Allele-specific binding assays (Need high-purity, sequence-verified heterodimer proteins) |
| Tolerogenic Nanoparticles | Anokion, Cour Pharmaceutical | Celiac Disease, Autoimmunity | Antigen-presentation assays (Need stable HLA-DQA1/DQB1 cell-line expression via Lentivirus) |
| TCR-like / Bispecifics | Immunocore, Roche | Autoimmune Immunotherapy | Off-target counter-screening (Need HLA-DRB1 and alternative HLA-DQ allele panels) |